Iprivask: Phase IV data

The open-label, single-arm, U.S. Phase IV DESIR-ABLE trial in 516 patients who required anticoagulation after major surgery or due to a medical illness with prolonged immobility showed that twice-daily 15 mg subcutaneous desirudin led to no major bleeding episodes, the primary endpoint. There were 2 fatal bleeding events, 1 of which was classified as possibly desirudin-related in a patient admitted for heart failure exacerbation. There were 10 deaths of which none were related to a venous thromboembolic event (VTE). Additionally, 8 patients experienced a new VTE. Serious adverse events occurred in 15.5% of patients, with 8 events leading to desirudin discontinuation. Patients received desirudin for an average of 5 days. Data were published in Clinical and Applied Thrombosis and Hemostasis. ...